Pluristem Therapeutics (PSTI) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Pluristem Therapeutics (NASDAQ:PSTI) from a hold rating to a sell rating in a research report sent to investors on Thursday, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group restated a buy rating and set a $3.00 target price on shares of Pluristem Therapeutics in a research note on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $3.19.

PSTI stock traded down $0.01 on Thursday, hitting $0.63. 1,325 shares of the company’s stock were exchanged, compared to its average volume of 583,097. Pluristem Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.52. The company has a market cap of $93.58 million, a price-to-earnings ratio of -2.52 and a beta of 1.13.

In other news, CEO Yaky Yanay purchased 71,429 shares of the company’s stock in a transaction on Monday, April 8th. The shares were acquired at an average price of $0.70 per share, for a total transaction of $50,000.30. Following the purchase, the chief executive officer now owns 4,253,045 shares in the company, valued at $2,977,131.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 6.70% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Van ECK Associates Corp grew its stake in Pluristem Therapeutics by 38.7% during the 4th quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 14,087 shares during the last quarter. Virtu Financial LLC grew its stake in Pluristem Therapeutics by 266.1% during the 1st quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 61,858 shares during the last quarter. Jane Street Group LLC grew its stake in Pluristem Therapeutics by 488.8% during the 1st quarter. Jane Street Group LLC now owns 119,692 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 99,363 shares during the last quarter. ETF Managers Group LLC boosted its stake in shares of Pluristem Therapeutics by 49.6% in the fourth quarter. ETF Managers Group LLC now owns 250,848 shares of the biotechnology company’s stock worth $192,000 after buying an additional 83,207 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Pluristem Therapeutics in the first quarter worth about $881,000. Institutional investors and hedge funds own 5.01% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Article: What is the Current Ratio?

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.